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Abstract 
Extracellular vesicles (EVs) that circulate in body fluids possess significant potential for disease diagnosis. 
Their use in clinical settings, however, has been limited owing to lack of simple and robust isolation 
methods. To rectify this problem, a centrifugal device for automatic, fast, and efficient isolation of EVs 
from whole-blood, called Exodisc-B is presented in this paper.  
Methods: The device comprises a built-in chamber to facilitate plasma separation and two nanoporous 
filters—one for removing larger particles and the other for enriching EVs. The performance of the device 
in comparison to ultracentrifugation (UC) was evaluated by analyzing the yield, purity, protein and RNA 
content of the isolated EVs. Additionally, the EV protein marker expressions were measured by ELISA 
and statistically analyzed to differentiate prostate cancer patients from healthy donors. 
Results: Compared with the UC technique, the proposed device is capable of isolating at least an order 
of magnitude higher number of EVs with about 30-fold higher mRNA count within 40 min. Sandwich 
ELISA of EV-specific membrane proteins—CD9-CD81—confirmed that Exodisc-B can isolate EVs from a 
volume of whole blood as low as 30 µL with a capture efficiency exceeding 75%. The device also facilitates 
temporal monitoring of tumor progression within live mouse xenograft models over a period of 13 
weeks while using minimal volumes of weekly collected blood samples. Further, in ELISA analyses of 
multiple cancer-related proteins, such as prostate-specific antigen (PSA), prostate-specific membrane 
antigen (PSMA), epithelial cell adhesion molecule (EpCAM), epidermal growth factor receptor 1 (EGFR1), 
and heat shock protein 90 (HSP90), extracted from EVs isolated from human plasma, 43 patients were 
differentiated from 30 healthy donors.  
Conclusion: The results demonstrated the ability of Exodisc-B to provide a rapid, sensitive, and 
point-of-care-type method for extracting intact EVs from small volumes of clinical blood samples for 
disease diagnosis and monitoring. 
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Introduction 
Extracellular vesicles (EVs), which are 
cell-driven nanoscale vesicles that carry bioactive 
molecules such as proteins and nucleic acids, play an 









Interest in the use of EVs as biomarkers in liquid 
biopsy for precision medicine has recently increased 
because of their abundance in most body fluids and 
their ability to provide disease-specific molecular 
information, thereby reflecting the real-time 
physiological status of patients [5-9]. In particular, 
EVs hold significant promise for use as less-invasive 
biomarkers for cancer diagnosis and monitoring 
[10-13]. Unlike tissue samples, which are comparati-
vely more invasive, prone to sampling errors owing to 
inherent spatial heterogeneity, unable to report 
temporal changes, and can only be obtained in limited 
quantities, circulating EVs provide collective 
information regarding cancers and can be repeatedly 
obtained from body fluids, thereby making real-time 
longitudinal monitoring of tumor progression and 
patient response to therapies more affordable [14-17]. 
However, a lack of fast, efficient, and robust 
EV-isolation techniques remains a major obstacle to 
widespread use of EV analysis as a routine test in 
research and clinical laboratories. 
Currently, ultracentrifugation (UC) is the most 
widely used method for isolating EVs that involves 
multiple, time-consuming, and labor-intensive 
high-speed centrifugation steps to remove cells, 
cellular debris, and apoptotic bodies. However, high 
centrifugal forces generated during the isolation 
process may cause EV fusion and alter their structure 
and function [18, 19]. Several alternatives to the UC 
process have been proposed to facilitate better EV 
isolation via the use of immunoaffinity capture [20, 
21], precipitation reagents [22], ultrafiltration [23], and 
microfluidics [24, 25]. Each of these techniques 
possesses its own advantages and disadvantages. For 
example, immunoaffinity capture can only isolate 
those EVs that contain the specific antibody used in 
their capture. Consequently, it is strongly dependent 
upon the sensitivity and the specificity of the antibody 
used, which may not provide consistent results 
considering the heterogeneity of EV population and 
the batch to batch variability. Similarly, the method 
involving the use of precipitation reagents requires 
less expensive equipment because of its reduced 
centrifugation speed requirements. However, 
polymer impurities imposed during the concerned 
process are highly unacceptable in many of the 
subsequent analysis procedures. EV-isolation 
methods employing ultrafiltration membranes 
require a large sample volume but return EVs with 
poor yields [26]. The use of microfluidic platforms 
suffers from relatively long processing times, 
incompatibility with downstream analyses, and a 
requirement for sophisticated fabrication steps. As 
can be inferred from the above discussion, currently 
available methods for EV isolation are not sufficiently 
mature to be considered acceptable for use in research 
and/or clinical applications, because their underlying 
protocol requires complicated manual operation, long 
processing times, and relatively large sample 
volumes. Furthermore, the quality of the enriched 
EVs samples is far from consistent. 
Blood is the most commonly used specimen for 
health monitoring and disease diagnosis. At present, 
UC is the most widely used method for EV isolation 
from blood-plasma samples as well as cell cultures, 
although significant concerns have been raised as 
regards poor yield, impurity, and reproducibility 
issues [27, 28]. The major technical challenge with 
regard to UC stems from the complexity of blood 
plasma samples, which contain not only EVs, but also 
cells, lipoprotein particles, and proteins. In addition, 
the rather high viscosity and density of plasma 
samples tend to impede the otherwise quick and 
efficient isolation protocols. During high-speed 
centrifugation, protein aggregates are generated and 
co-precipitated along with EVs and lipoprotein 
particles of a similar size and density, thereby 
resulting in poor quantitative and qualitative 
performance during downstream analysis. Therefore, 
there is a critical and urgent need for a reliable 
method of isolating EVs from blood samples. 
To realize robust and efficient isolation of intact 
EVs, a fully integrated centrifugal microfluidic device, 
called Exodisc, has previously been demonstrated to 
enrich EVs from urine and cell-culture supernatant 
within 30 min [29]. Exodisc can isolate EVs at 
relatively low g-force values (less than 500 g) via 
sequential and tangential flow-filtration processes 
involving the use of two nanofilters with pore 
diameters measuring 600 nm and 20 nm, positioned 
such that the direction of flow through the membrane 
remains perpendicular to that of the centrifugal 
pumping force. The results of subsequent quantitative 
analyses, including nanoparticle-tracking analysis 
(NTA), enzyme-linked immunosorbent assay 
(ELISA), and real-time polymerase chain reaction 
(PCR) of mRNA confirmed that a process incorp-
orating Exodisc results in concentration and purity of 
isolated EVs that are significantly higher than those of 
the UC process [29].  
In this study, Exodisc-B and Exodisc-P—which 
are optimized for EV isolation from blood and plasma 
samples, respectively, were developed. Exodisc-P, 
which is identical to Exodisc-B but has no blood 
separation chamber, is employed when pre-stored 
plasma samples are used. Exodisc-B/P can be 
operated using a point-of-care, small bench-top-sized 
operation system. With one simple manual injection 
of a whole-blood sample (30–600 μL) into Exodisc-B, 
the disc spinning system separates plasma and 





enriches EVs within 40 min in a fully automated 
manner. Exodisc-B/P can be operated by any 
personnel without the need for special training. This 
study demonstrates that using Exodisc-B/P can result 
in unbiased, intact EVs with higher yield and purity 
and higher mRNA and protein content than the UC 
process.  
In addition, continuous and real-time monitor-
ing of tumor progression was realized using the EVs 
isolated from minimal amounts of plasma (< 30 μL 
per week) extracted from mouse xenograft models 
over a period of 13 weeks. The proof of concept of a 
longitudinal study performed on small live animals 
clearly demonstrated the unique and important 
advantage of the use of Exodisc-B/P, which can 
directly isolate EVs from a small volume of 
blood/plasma in a robust manner. In addition, the 
EVs contained in the plasma of 43 patients diagnosed 
with prostate cancer and 30 healthy donors were 
isolated using Exodisc-P and further analyzed for 
specific protein markers, including EV markers, CD9, 
CD63, CD81, along with cancer markers, such as 
prostate-specific antigen (PSA), prostate specific 
membrane antigen (PSMA), epithelial cell adhesion 
molecule (EpCAM), epidermal growth factor receptor 
1 (EGFR1), and heat shock protein 90 (HSP90), via 
ELISA. The test results further confirmed the potential 
clinical utility of Exodisc-B/P for liquid biopsy. 
Results and Discussion 
Fully Automated EV Enrichment from 
Blood/Plasma Samples via Sequential, 
Tangential Flow-Filtration 
 
The fully automated process for EV isolation 
from whole-blood samples using Exodisc-B and a 
benchtop spinning machine is depicted in Figure 1, 
along with the working principle of the sequential, 
tangential flow-filtration on a spinning disc. 
Exodisc-B comprises four sample storage and two 
filtration chambers connected by channels, with five 
individually addressable diaphragm (ID) valves (as 
depicted in Figure S1 and S2) for the automatic 
control of sequential transfer of liquid samples 
(Figure S3) [30, 31]. The entire process of EV isolation 
from whole blood, including plasma separation, 
pre-filtration, EV enrichment, washing, and elution, is 
fully automated and integrated on the disc (as 
described in Figure S3 and presented in Table S1). 
Plasma is separated from whole blood (Figure S3A) 
and transported through the filters to the waste 
chambers (Figures S3B–S3C). During filtration, large 
particles are trapped by the first filter, while residual 
proteins and lipoproteins are removed by a second 
filter. Following filtration, the EVs are washed (Figure 
S3D), and the solution at the bottom of the membrane 
is removed (Figure S3E). Finally, the enriched EVs are 
transferred to the elution chamber (Figure S3F). This 
entire EV enrichment process can be completed 
within 10–40 min depending upon the volume 
(30–600 μL) of the whole-blood sample used (refer to 
Supplementary Movie S1 for the complete process). 
Exodisc-P (Figures S1B-S1C) is identical to Exodisc-B 
but has no blood separation chamber. 
 
Figure 1. (A) Schematic demonstration of the process of EV isolation from whole blood on a disc using table-top-sized, custom-made spinning device, along with 
methods of subsequent analysis. (B) Photograph of Exodisc-B; schematic of Exodisc-B showing detailed microfluidic features and the working principle of the 
centrifugal double-filtration system. 
 






Figure 2. Membrane selection and comparison of EV yield and purity prepared 
via Exodisc (D20 and D100) and UC (ultracentrifugation). D20 denotes Exodisc 
integrated with 20 nm AAO membrane operated at 3000 rpm, D100 denotes 
Exodisc integrated with 100 nm AAO membrane and operated at 1200 rpm. 
(A) Number of EVs isolated by Exodisc and capture efficiency calculated based 
on CD9-CD81 ELISA data (D20 and D100 produced more EVs than UC), total 
protein quantification based on BCA measurements (higher protein 
contamination demonstrated in D20), purity measured by number of particles 
per total protein content (D100 yields the highest); (B) SEM image of EVs 
isolated via D100. (C) Size-distribution profiles of EVs isolated via UC and 
Exodisc. (D) Plot of inverse flow rate (t/V) as a function of plasma and urine 
volume; Error bars represent the mean ± s.e.m. 
 
Optimization of Filter Membrane and Spinning 
Condition 
In our previous study concerning Exodisc for EV 
isolation from urine and cell-culture media, the EVs 
were enriched on AAO membrane with pore 
diameters of 20 nm by spinning the disc at an 
optimum spin speed of 3000 rpm (412 g), termed D20 
in this paper [29]. Barely any flow resistance existed 
when the EVs were enriched from urine samples 
(measuring less than 10 mL) under this condition. 
However, the same membrane was presumed to be 
not ideal for isolating EVs from plasma because blood 
plasma contains numerous proteins, including 
albumins (measuring approximately 3.8 nm in 
diameter and 15 nm in length) and globulins/globular 
proteins (measuring approximately 5–14 nm in 
diameter). To test this, Exodisc devices were 
constructed comprising AAO filters with larger pore 
diameters (100 nm) to isolate the EVs from 
blood-plasma samples. The minimum spin speed 
required for a complete sample transfer was 1200 rpm 
(66 g) for Exodisc equipped with membranes with 
pore diameters of 100 nm, D100. The capture 
efficiency decreased as the spinning speed increased 
though the size distribution remained similar and no 
aggregation observed in all the cases. (Figure S4).  
Subsequently, the EVs isolated using Exodiscs 
(D20 and D100) and the UC process were compared in 
terms of particle number, capture efficiency, protein 
content, purity, process time, and particle-size 
distribution (Figure 2A and 2C). In all experiments, 
the EVs were isolated from the plasma samples 
obtained from a single healthy donor spiked with a 
known quantity of LNCaP cell-culture supernatant 
(LNEV). The plasma samples spiked with LNEV were 
used only for the performance evaluation to mimic 
the high particle concentration of the plasma sample 
from cancer patients and to obtain a large quantity of 
the same sample for direct comparison of the different 
disc operation conditions. In real sample tests using 
the plasma sample obtained from xenograft mouse or 
cancer patients or healthy donors, the plasma samples 
were used directly. 
The number of particles isolated in Exodiscs was 
more than two orders of magnitude higher than that 
isolated using UC (Figure 2A). CD9-CD81 sandwich 
ELISA demonstrated capture efficiencies of 
approximately 88 ± 0.4%, 76 ± 2.8%, and 15 ± 0.4% for 
the D20, D100, and UC processes, respectively. The 
highest amount of total plasma proteins was retained 
within the samples prepared using D20, as the pore 
size is too small to filter off the plasma protein 
contaminants. The fraction of plasma proteins 
contained within the EV sample prepared by D100 
from the input plasma sample (6 ± 0.1%) in 
comparison to that within EVs isolated via UC (4 ± 
0.1%) could be attributable to the large number of 
particles enriched, which resulted in the isolation of 
very pure EVs in the D100 case. In addition, D100 
showed low coefficient of variation (CV) of <7% for all 
the tested devices (Figure S5). The SEM images of 20 
nm and 100 nm filters after plasma filtration on D20 
and D100, respectively, (Figure S6A) clearly 
demonstrates that significant amount of plasma 
protein contaminants remained on the 20 nm filter 
along with the EVs. The overall EV-isolation process 
for D100 case was less than 30 min compared to 6 h 
and 70 min for UC and D20, respectively. Figure 2B 
and Figure S6B depict representative scanning 
electron microscopy (SEM) images of the EVs isolated 
using D100. Interestingly, the nanoparticle tracking 
analysis (NTA) data demonstrated no significant 
difference in the particle-size distributions of the EVs 
enriched by two different conditions of Exodisc 
operation (Figure 2C and Figure S7).  
Membrane-filtration processes are widely used 
in industrial applications such as water treatment and 
particle separation. Typically, the filtration mechan-





ism for liquid samples containing abundant particles 
can be explained by the “cake filtration” theory, 
wherein the curve representing the inverse flow rate 
(t/V) versus the cumulative volume (V) exhibits a 
linear relationship with the slope defined as the 





+ 𝜂𝜂𝜂𝜂𝐶𝐶𝑃𝑃2∆𝑃𝑃𝑃𝑃2 𝑉𝑉 
where t denotes the filtration time, η is the viscosity, 
Rm denotes the membrane resistance, ΔP denotes the 
transmembrane pressure, A denotes the membrane 
area; α denotes the specific resistance of the cake 
deposited, and CP denotes the concentration of the 
particles within the feed solution [32-35]. MFI is one of 
the most common fouling indices for predicting 
fouling problems concerning the membrane-filtration 
process. As shown in Figure 2D, the filtration time per 
unit volume of urine sample remains constant even 
up to 10 mL, which suggests that there is no 
membrane fouling. However, typical cake filtration 
behaviors were observed for plasma sample filtration 
for both D20 and D100, which suggests that the 
effective pore diameter could be much smaller than 
the original filter diameter. The MFI for D20 was 
estimated to be more than two times higher than its 
corresponding value for D100, indicating that 
membrane fouling via D20 results in less efficient 
particle filtration [33, 35]. 
Comparison of Plasma-Driven EVs isolated by 
Exodisc-P and UC 
Following optimization of the membrane type 
and spinning conditions, the performance of 
Exodisc-P was compared to that of the UC process 
with regard to isolation of EVs from plasma samples 
spiked with a known amount of LNEV (Figure S8). 
Isolated EV samples were analyzed using NTA 
(Figure 3A), CD9-CD81 sandwich ELISA (Figure 3B), 
and BCA (Figure 3C). As observed during these 
analyses, the EV samples isolated using Exodisc-P 
demonstrated a broad linear dynamic range in 
volumes measuring between 5 and 200 µL of plasma 
sample. A detectable signal was obtained for EV 
isolation from samples measuring as small as 10 µL of 
plasma, thereby demonstrating the utility of Exodisc- 
P for isolating EVs from small sample volumes. 
 
 
Figure 3. Analysis results for EVs isolated by Exodisc-B/P and UC. (A) NTA analysis, (B) CD9-CD81 ELISA, (C) BCA protein assay, (D) quantitative (ELISA) and 
qualitative (Western blot) analysis of albumin contamination of EVs prepared using Exodisc-P and UC, (E) RNA analysis of EVs of LNCaP cell-derived EVs-spiked 
plasma, (F) RT-PCR results, (G) NTA analysis, (H) CD9-CD81 ELISA (Note: Figures A–F show cases of plasma samples spiked with LNCaP cell-derived EVs, whereas 
(G–H) show cases of whole-blood clinical samples obtained from nine patients with cancer and five healthy donors, HD = healthy donors, P = patients). (A–D, F) 
markers/bars and error bars represent the mean ± s.e.m.; and (G, H) the box plot indicates the mean (white square within the box), 75th percentile (top line of the 
box), median (middle line of the box), 25th percentile (bottom line of the box), 5th and 95th percentiles (whiskers), and minimum and maximum measurements 
(crosses). Significance was tested by Student’s t-test with p < 0.05 and p < 0.01 noted as * and **, respectively. 





In addition, the EVs prepared using Exodisc-P 
demonstrated lower albumin content (0.61 ± 0.07 
µg/mL) compared to those isolated via UC (9.03 ± 
0.78 µg/mL), as measured by ELISA as well as 
western blot (Figure 3D). Moreover, when the EVs 
isolated from the 200 µL plasma sample were 
analyzed for proteins—via gel electrophoresis (Figure 
S9) and total RNA content—using a bioanalyzer 
(Figure 3E), the results demonstrated the presence of 
highly enriched proteins within the EV samples 
isolated by Exodisc-P along with a total RNA count of 
five times were contained within the UC-isolated 
sample. An RT-PCR analysis to determine the CT 
values for GAPDH, CD9, CD63, and CD81 using RNA 
isolated from the EV samples demonstrated that the 
Exodisc-P-isolated EV sample contained more than 
30-times higher mRNA concentration than those 
within the UC-isolated sample (Figure 3F, Table S2). 
When the diluted plasma samples were used, the 
capture efficiency did not alter, while the filtration 
time was increased (Figure S10). 
The EVs from clinical samples, including those 
obtained from nine cancer patients and five healthy 
donors were isolated and analyzed to further validate 
the performance of Exodisc-B. The obtained yield and 
EV protein markers were, once again, analyzed via 
NTA and CD9-CD81 sandwich ELISA. As depicted in 
Figure 3G and 3H, the proposed Exodisc-B isolated 
more particles with higher CD9-CD81 sandwich 
ELISA signals than the UC process. The total number 
of particles isolated on the disc was at least five times 
more than the corresponding number isolated via UC. 
Although no significant difference existed between 
the total number of particles collected from patients 
and healthy donors (Figure 3G), the CD9-CD81 
sandwich ELISA signals demonstrated significant 
differences between healthy- and cancer-patient EVs 
isolated via UC, and use of Exodisc-B with higher 
signal and discrimination power was associated with 
the Exodisc-B-isolated sample (Figure 3H). These 
results suggest that Exodisc-B can be effectively used 
for the isolation of the EVs from clinical samples for 
subsequent analysis. 
Monitoring Tumor Growth in Live Mouse 
Xenograft Models  
The EVs hold significant potential for use in 
cancer diagnosis and monitoring; hence demonstra-
ting a good correlation between the EV biomarker 
concentration and tumor burden has become critical 
[9]. Using the proposed Exodisc-B/P devices to 
efficiently isolate EVs from small blood/plasma 
volumes, this study demonstrates a time-course 
monitoring of EV proteins associated with tumor 
progression in live mouse models. Performing such 
an analysis has not previously been practical because 
of the highly sophisticated and complex EV-isolation 
processes and large sample-volume requirements of 
conventional EV-analysis methods. In this study, 
human PC3 cells representative of prostate cancer 
were subcutaneously injected into mice, and blood 
samples (measuring less than 100 µL) were collected 
each week while recording the body weight and 
tumor volume of each mouse (Figure 4A–4D). Plasma 
samples were collected from two groups of three 
tumor-bearing and three control mice on a weekly 
basis and stored at -80 ℃ to facilitate the use of 
conventional ELISA to measure the expression levels 
of EV protein markers. EV isolation from plasma was 
performed using Exodisc-P. The temporal changes in 
the expression levels of CD9 and CD81 along with 
those of other cancer markers, including PSMA, 
EGFR1, and HSP90, were analyzed from the lysates of 
the EVs isolated from individual tumor-bearing and 
control mice via direct ELISA (Figure 4E–4I). Three 
cancer-specific proteins—PSMA, EGFR1, and 
HSP90—demonstrated a temporal increase in 
tumor-bearing mice as early as the second week. In 
contrast, no significant changes were observed in their 
expression levels in the control mice, thereby 
indicating the diagnostic potential of EV markers with 
regard to prostate-cancer progression.  
Protein-Marker Profiling of EVs from Cancer 
Patients’ Plasma 
The plasma samples drawn from 43 
prostate-cancer (PCa) patients and 30 healthy donors 
(HD) were analyzed to investigate whether the prop-
osed point-of-care Exodisc-P detects tumor-derived 
EVs from the plasma of cancer patients (refer to Table 
S3 for sample information). Prostate cancer, which is 
one of the most common types of cancers in men [36], 
is more likely to be successfully treated if diagnosed 
early. PSA testing along with digital rectal 
examination (DRE) constitute a common method used 
for early detection of prostate cancer, despite the 
lower sensitivity and specificity of the two methods 
[37]. Therefore, the lysates of the EVs isolated from 
prostate-cancer plasma samples were analyzed by 
direct ELISA for containment of cancer-associated 
markers (e.g., PSA, PSMA, EpCAM, EGFR1, and 
HSP90) along with the EV-specific markers, (e.g., 
CD9, CD63, and CD81) to identify the EV markers 
that demonstrate a higher diagnostic accuracy for 
prostate cancer. 
Figure 5A depicts a heat map of normalized 
optical density (OD) measurement of proteins sorted 
by the HSP90 expression levels within each sample. 
As can be observed, each patient demonstrated a 
distinct profile for tested markers, because the 





expression levels of each marker differed in each 
individual. All markers used for analysis herein could 
significantly differentiate PCa from HD with 
representative p-values of less than 0.05 (CD81), 0.01 
(CD63), 0.001 (CD9 and EGFR1), and 0.0001 (PSMA, 
PSA, EpCAM, and HSP90) (Figure 5B). Subsequently, 
receiver operating characteristic (ROC) analysis was 
used to determine the sensitivity, specificity, and 
accuracy of each individual marker (Figure 5C and 
S11), and the area under the ROC curve (AUC) for all 
markers was plotted with HSP90 demonstrating the 
highest value of 92% (Figure 5D). Figure 5E shows a 
waterfall plot of the HSP90 expression sorted from 
high (left) to low (right) for all samples, with each bar 
representing one individual.  
The ROC curves corresponding to each marker 
were depicted separately with the corresponding 
values of their sensitivity, specificity, etc. listed in the 
form of a table in Figure S11. The HSP90 marker was 
observed to be the most sensitive in terms of all 
evaluation criteria. When multiple markers such as 
CD63, PSMA, and PSA were tested together with 
HSP90 using support vector machine (SVM) analysis, 
a combination of CD63+PSA+PSMA+HSP90 seems to 
be the most sensitive but the increase was rather 
minor compared to the HSP90 only case (Figure S12). 
The Spearman correlation of all markers tested 
resulted in generation of a few positive correlations 
for PCa samples with only one positive correlation 
(CD63–PSA) for HD samples (Figure S13). No 
correlation was observed between the EV-marker 
expression levels and the preoperative plasma-PSA 
levels of PCa patients (Figure S14). Similarly, no 
correlations were observed between other 
pathological factors such as tumor volume, Gleason 
score, tumor stage, and the expression levels of 
markers tested in this study (data not shown). 
However, the PCa samples with lymphatic/ 
perineural invasion demonstrated significantly higher 
expression levels of CD63, EGFR1, EpCAM, and 
HSP90 along with a larger tumor volume compared to 





Figure 4. (A) Monitoring of tumor progression using plasma-driven EVs from mice xenograft models. (B) Representative images of control and a solid tumor-bearing 
mouse with the tumor mass, 13 weeks after subcutaneous inoculation of PC3 cells, tumor masses were removed and photographed. (C) Body-weight comparison 
between control and tumor-bearing mice over period after inoculation. (D) Increase in tumor volume over time observed in tumor-bearing mice. (E–I) direct ELISA 
results for EV and cancer-specific markers from lysates of isolated EVs. Error bars represent the mean ± s.e.m. 






Figure 5. Protein typing of human-plasma-driven EVs extracted from prostate-cancer patients and healthy donors. (A) Heat map demonstrating normalized OD 
measurements sorting along HSP90 expression level for three EV markers CD81, CD63, and CD9 and five cancer markers EGFR1, PSMA, PSA, EpCAM, and HSP90 
measured from lysates of EVs using direct ELISA. (B) Eight markers validated for 43 prostate-cancer patients and 30 healthy donors using direct ELISA; The box plot 
indicates the 75th percentile (top line of the box), median (middle line of the box), 25th percentile (bottom line of the box), and 5th and 95th percentiles (whiskers) 
with raw measurements in scattered dots. Significance was tested by Student’s t-test with p < 0.05, p < 0.01, p < 0.001, and p < 0.0001 marked in *, **, ***, and ****, 
respectively. (C) ROC curves obtained for eight markers. (D) AUCs calculated for eight markers. (E) HSP90 expression in patient-plasma-driven EV (red) and 
healthy-donor-plasma-driven EV (black) demonstrated as waterfall plot. Cut-off (OD = 0.087) was obtained based on negative likelihood ratio (refer to Figure S11). 
 
It has also been reported that EVs isolated from 
plasma of prostate cancer patients showed higher 
protein expression of PSA [38], PSMA [39], and EGFR 
[40]. In this study, the ROC analysis showed that 
prostate-specific (PSMA and PSA) and tumor-specific 
(EpCAM) EV markers exhibited relatively good AUC 
values: 0.78, 0.81, and 0.81 for PSMA, PSA, and 
EpCAM, respectively. In addition, interestingly, 
HSP90 demonstrated the highest sensitivity (86%), 
specificity (90%), accuracy (88%), and AUC (0.92), of 
all the test markers for the small sample cohort used 
in this study. HSP90, which is a member of heat-shock 
proteins, is known for its chaperoning activity to 
protect a number of proteins involved in cancer 
progression, thereby promoting cancer-cell survival 
[41-43]. It contains a number of client proteins, 
including the androgen receptor (AR), and 
participates in the development of resistance to cancer 
treatment. The inhibition of the HSP90-depleted 
AR-splice variant7 (AR-V7) and AR-full length in 
prostate-cancer cell lines expressing this variant have 
previously been demonstrated that [44]. Although 
studies are presently underway to target HSP90 in 
cancer therapy [45, 46], its utility as a diagnostic 
marker has not yet been reported for prostate cancer, 
except in a few recent studies that have demonstrated 
its presence in elevated levels within the serum of 
prostate cancer patients [47] and in exosomes released 
from prostate cancer cell lines that grow under 
hypoxic conditions [48]. In the case of EVs secreted 





from lymph‐node‐metastatic oral squamous cell 
carcinoma cells, it is reported that cancer cells secrete 
HSP90-enriched EVs, which play a critical role in 
tumor progression [49]. Moreover, the higher 
expression of HSP90 in the EVs were strongly 
correlated with poor prognosis of patients with head 
and neck cancers [49]. Additionally, HSP90 was also 
recognized as a distinctive exosome-specific melan-
oma signature [50]. Consequently, further research 
needs to be performed with a large patient cohort to 
validate the utility of HSP90 as a diagnostic marker in 
prostate-cancer detection. 
Conclusions 
EVs are increasingly being recognized as 
potentially valuable sources of biomarkers for early 
diagnosis of diseases as well as therapy monitoring [6, 
12, 13, 51, 52]. However, the availability of efficient 
and user-friendly EV-isolation methods remains a 
major challenge inhibiting widespread acceptance of 
EV-analysis techniques in research laboratories and 
clinical translations. This study proposed Exodisc-B as 
a device that is capable of effectively performing 
automatic EV isolation from whole-blood samples in a 
point-of-care manner. Exodisc-B offers a rather 
simplistic, fast, and efficient means of realizing intact 
EV isolation in a reproducible manner from small 
sample volumes measuring as small as 30 µL of whole 
blood. Using the proposed device, the entire process 
of EV enrichment from whole-blood samples can be 
completed within 10–40 min, depending on the 
blood-sample volume used (30–600 µL), with a single 
manual sample injection step. The outputted highly 
enriched intact EVs can subsequently directly be used 
for conventional analyses, such as NTA, ELISA, and 
PCR, thereby demonstrating significantly higher 
performance than EV samples prepared via UC.  
Taking advantage of the proposed device's 
ability to perform highly efficient enrichment of EVs 
from small volumes of plasma, the temporal changes 
in protein levels within the EVs of tumor-bearing mice 
were continuously monitored over a period of 13 
weeks. The temporal analysis of such systems serves 
to improve the accuracy of biomarkers and aids in the 
monitoring of tumor growth and cancer progression. 
This study demonstrates that use of the proposed 
Exodisc-P can facilitate EV extraction from a minimal 
volume of plasma samples (less than 30 μL) collected 
weekly in accordance with the least painful protocol 
to be approved by the Institutional Animal Use and 
Care committee. The EVs thus isolated can be 
subsequently analyzed via conventional analysis 
techniques. As proof of concept, time-course ELISA 
measurements of five protein markers (CD9, CD81, 
PSMA, EGFR, and HSP-90) were performed. The 
results demonstrated a significant increase in 
cancer-associated markers (i.e., PSMA, EGFR, and 
HSP-90) in as early as two weeks after inoculation of 
tumor cells. The results of this study suggest that the 
Exodisc-B/P device can be routinely used in small 
animal cancer research studies, such as those geared 
toward early diagnosis of disease and continuous 
monitoring of drug response. 
Furthermore, EV-specific protein markers such 
as CD9, CD63, and CD81, and cancer markers 
associated with EVs, including EpCAM, PSMA, PSA, 
HSP90, and EGFR1, were highly expressed in the EVs 
isolated from the plasma samples of patients suffering 
from prostate cancer compared to those isolated from 
plasma samples of age-matched healthy donors. 
Among the tested protein markers, cancer-associated 
protein markers, such as PSMA (AUC = 0.78), 
EpCAM (AUC = 0.81), PSA (AUC = 0.81), and HSP90 
(AUC = 0.92), from the EVs performed satisfactorily 
with regard to differentiating cancer patients from 
healthy donors, clearly demonstrating that plasma- 
driven EVs are a valuable source of diagnostically 
significant biomarkers. 
While it is promising and suggestive that 
Exodisc-B/P can be used to perform simple, rapid, 
and noninvasive blood tests facilitating early 
diagnosis of prostate cancer, we do acknowledge that 
its realization requires further prospective studies 
with more clinical samples and a larger cohort, 
including patients demonstrating early stages of 
prostate as well as other types of cancer. Though 
Exodisc-B/P can provide EVs in much higher yield 
and purity compared to UC method, it still contains a 
mixture of EVs with different sizes and subsets as well 
as non-EV contaminants such as low-density 
lipoprotein, which needs to be further improved. 
While it has a significant advantage for the 
enrichment of the EVs from a small volume of plasma 
sample, processing plasma samples larger than 1 mL 
is not practically possible with the current design of 
the disc. In addition, although the capability of 
Exodisc-B/P with regard to the continuous 
monitoring of tumor progression in small animals as 
well as diagnosis of human patients with prostate 
cancer has been well demonstrated, the proposed 
device must also be useful in terms of therapy 
monitoring and drug-resistance prediction, 
demonstration of which requires further studies to be 
performed with more clinical samples. Nevertheless, 
the current proof-of-concept study demonstrates a 
promising frontier with regard to point-of-care EV 
analysis offered by Exodisc-B/P capable of providing 
fully automated, fast, sensitive, and robust isolation of 
intact and subsequent-analysis-compatible EVs from 
whole-blood/plasma samples. 





Materials and Methods 
Design, fabrication and operation of the disc 
The Exodisc structure was designed using a 
three-dimensional (3D) computer-aided design (CAD) 
program and fabricated by means of a CNC milling 
machine (M&I CNC Lab, Osan, South Korea). The top, 
middle, and bottom layers of polycarbonate (PC; 
IComponents Co. Ltd., Pyongtaek, South Korea) were 
milled in accordance with the 3D CAD model. Post 
milling, all layers were laminated using two pressure- 
sensitive, double-sided adhesives (DFM 200 clear 150 
POLY H-9 V-95; FLEXcon, Spencer, MA, USA) and a 
customized pressing apparatus (Figure S1). The 
general procedure of fabricating a lab-on-a-disc 
integrated with a membrane filter has been described 
in our previously published works [29, 53]. Briefly, 
the procedure can be described as follows: each layer 
of the Exodisc device is fabricated via CNC milling, 
and the reverse side of the filtration chamber was 
carved for insertion of commercially available 
membranes, including a track-etched PC membrane 
(13-mm diameter and 0.6-μm pore size; SPI Supplies, 
West Chester, PA, USA) and an AAO membrane 
(13-mm diameter and 0.02- or 0.1-μm pore size; 
Whatman; Thermo Fisher Scientific, Waltham, MA, 
USA), as filters I and II, respectively. Reversible ID 
valves were automatically actuated in the same 
manner as that reported in extant studies (Figure S2) 
[30, 31]. 
The overall process of the EV enrichment from 
the whole-blood samples on a spinning disc was 
summarized in Figure S3 and Table S1. First, plasma 
samples (200 µL) were obtained from whole-blood 
(600 µL) by spinning the disc at 3600 rpm for 5 min 
(Figure S3A). Following plasma separation, valve #1 
was opened, and the disc was made to rotate via spin 
step #2 to transfer 200 µL of separated plasma into the 
pre-filtration chamber (Figure S3B). Valve #2 was 
then opened, and the loaded plasma solution was 
transferred through the 600-nm TEPC and 100-nm 
AAO membranes into the waste chamber via spin 
step #3 (Figure S3C). During filtration, large particles 
are trapped by the 600-nm filter, and residual proteins 
and lipoproteins are removed by the 100-nm AAO 
filter. After filtration, valve #3 was opened, and a 
washing solution (1.6-mL) was transferred through 
the EV filtration chamber into the waste chamber via 
spin step #4 (Figure S3D). Next, the bottom solution 
below the AAO filter was removed via spin step #5 to 
eliminate impurities (Figure S3E). Finally, the 
enriched-plasma EVs were transferred into the elution 
chamber (Figure S3F).  
Clinical samples preparation, handling, and 
storage 
Whole-blood was collected from five healthy 
donors, three prostate cancer patients, and six lung 
cancer patients. The plasma samples were collected 
from 30 healthy donors and 43 prostate-cancer 
patients. All blood and plasma samples were obtained 
following approval by an institutional review board 
(IRB 1702-008-051). The biospecimens and correspo-
nding data used in this study were provided by the 
Biobank of Pusan National University Hospital—a 
member of the Korea Biobank Network. Cancer- 
patient blood samples were obtained from the Pusan 
National University Hospital (IRB H1612-019-049), 
while blood/plasma samples of healthy donors were 
obtained from commercial sources (Innovative 
Research, MI) and volunteers at the Yeungnam 
University Medical Center (IRB 2018-04-011). Blood 
samples measuring 3 mL each were collected in a 
vacutainer EDTA collection tube and processed 
within 2 h after collection.  
Preparation of LNEVs for spiking experiments  
The EVs used for spiking whole-blood samples 
were isolated from LNCaP cells obtained from ATCC 
and cultured at the Roswell Park Memorial Institute 
medium (Gibco, Thermo Fisher Scientific) 
supplemented with 10% Exo-Free fetal bovine serum 
(Systems Biosciences Inc, CA, USA) and 1% 
antibiotics/antimycotics. The cells were incubated at 
37 °C with 5% CO2. The cell-culture supernatant was 
collected after 48 h of culture and centrifuged at 300 g 
for 10 min to remove dead cells, followed by spinning 
at 2,000 g for 15 min at 4 °C to completely remove 
dead cells and cellular debris. The supernatant was 
filtered through a 600-nm filter to remove vesicles 
measuring more than 600 nm. The EVs were enriched 
using a disc comprising a 20-nm AAO membrane 
filter. A standard curve was drawn for CD9-CD81 
ELISA using isolated EVs (Figure S8), and a known 
amount of enriched EVs was used to spike 
whole-blood samples for process optimization.  
Ultracentrifugation (UC)  
The EVs were isolated from whole-blood 
samples with or without spiked LNEV using the 
standard ultracentrifugation process. For plasma 
preparation, all steps were performed at RT. The 
whole-blood samples were initially centrifuged at 500 
g for 10 min at RT to separate cellular components, 
and the supernatant, which contained platelet-rich 
plasma, was centrifuged twice at 2500 g for 15 min 
each at RT to remove platelets. The clear plasma was 
filtered through a 600-nm syringe filter and 
centrifuged in a Beckman Coulter Ultracentrifuge at 





120,000 g for 90 min at 4 °C using a TLA 120.2 Ti 
fixed-angle rotor (Beckman Coulter) and 1.2 mL 
polycarbonate ultracentrifuge tubes to pellet EVs. To 
eliminate protein contaminants, the supernatant was 
carefully removed, and the EV pellets were 
resuspended in PBS and centrifuged again at 120,000 
g for 90 min at 4 °C. The supernatant was removed, 
and the resulting EV pellets were resuspended in the 
desired volume of PBS to facilitate further analysis. 
Nanoparticle tracking analysis (NTA) 
The concentration and the size distribution of 
EVs were measured using an NTA system (Nanosight 
NS500; Malvern Instruments, Malvern, UK). The 
isolated EV samples were vortexed and diluted with 
200-nm pre-filtered PBS to obtain the recommended 
25–100 particles/frame of the NTA system. All 
measurements were performed under identical 
settings to ensure consistent results. Each sample was 
analyzed thrice, and mean values were plotted.  
CD9-CD81 sandwich ELISA  
An EVs solution was prepared to maintain 
identical input volumes for both isolation methods 
and to compare the efficiencies of the two EVs 
isolation methods (Exodisc and UC). A 96-well plate 
(Corning Inc., NY, USA, cat#3590) was coated with 50 
μL of coating antibodies (10 μg/mL anti-CD9 in PBS 
buffer; MEM 61; Abcam, Cambridge, UK) and 
incubated overnight at 4 °C. The following morning, 
the plate was blocked with 1% bovine serum albumin 
(BSA)-PBS buffer at 37 °C for 1 h. After washing with 
0.1% BSA-PBS buffer (washing buffer), the plate was 
further incubated with an EV solution in PBS buffer 
(50 μL) at RT for 2 h. Following removal of the 
solution, the plate was washed twice with washing 
buffer, followed by addition of biotin-conjugated 
secondary antibodies (anti-CD81; LifeSpan Biosci-
ences, Inc., Seattle, WA, USA) in PBS buffer (50 μL; 
500 ng/mL), and incubated at RT for 1 h. After 
washing thrice with the washing buffer, the plate was 
incubated with a solution of HRP-conjugated 
streptavidin in PBS buffer (50 μL; 1:500 for LNEV 
spiked samples and 1:200 for clinical samples) at RT 
for 30 min followed by three washing procedures 
using the washing buffer. TMB solution (50 μL) was 
subsequently added, and the plate was incubated at 
RT for 15 min, following which, 50 μL of stop solution 
was added to each well. Solution absorbance was 
measured using a plate reader spectrophotometer 
(TECAN, Morrisville, NC, USA) at 450 nm. 
SEM imaging 
The EVs enriched on D100 were fixed using 4% 
paraformaldehyde in PBS buffer at RT for 20 min. 
Subsequently, the EVs were washed once with PBS 
and successively subjected to serial dehydration with 
50%, 70%, 90%, and 100% ethanol for 15 min each. 
Finally, 100% ethanol treatment was repeated, 
followed by drying of samples. The SEM images of 
the EVs isolated on D100 were acquired using the 
SU-8220 cold FE-SEM instrument (Hitachi high 
technologies, Japan). 
Direct ELISA for EV & cancer specific markers 
The EVs were lysed for 30 min using RIPA buffer 
containing 1% proteinase inhibitors on ice with gentle 
vortices generated at 10-min intervals. A 50-µL 
volume of 1:50 diluted EV lysates in PBS was used to 
coat each well of a 96-well plate (Corning Inc., NY, 
USA, cat#3590) and incubated overnight at 4 °C. The 
following morning, the plate was blocked with 1% 
bovine serum albumin (BSA)-PBS buffer at RT for 1 h. 
After washing with 0.1% BSA-PBS buffer (washing 
buffer), the plate was loaded with primary antibodies 
(Table S4) in PBS buffer (50 μL; 500 ng/mL) and 
incubated at RT for 1 h. After washing thrice with 
washing buffer, the plate was incubated along with a 
solution of HRP-conjugated detection antibodies in 
PBS buffer (50 μL) at RT for 20 min, followed by three 
washing procedures using the washing buffer. TMB 
solution (50 μL) was then added, and the plate was, 
again, incubated at RT for 15 min. Following which, 
50 μL of stop solution was added to each well. 
Solution absorbance was measured using a plate 
reader spectrophotometer at 450 nm. 
Mouse xenograft model to study tumor 
progression 
Mice were cared for in compliance with the 
protocol approved by the Institutional Animal Use 
and Care committee of UNIST (IACUC-2013-013). To 
perform EV isolation and monitor protein markers 
within plasma, 5 × 106 PC3 cells in 200 µL of PBS per 
mouse were subcutaneously injected into the left flank 
of three 8-week-old male nude mice. Likewise, in the 
control group, 200 µL PBS was injected into each of 
the three mice in the group. The blood samples 
(approximately 100 µL) were collected every week via 
retro-orbital blood collection for 13 weeks. Subsequ-
ently, the animals were sacrificed, and tumor masses 
were removed and photographed. Calipers were used 
to determine the tumor length and width, Tumor 
volume was estimated using the volume 
formula—D/2 × d2—where D denotes the largest 
diameter, while d refers to the shortest diameter. 
Western blotting and SDS-PAGE gel 
Exosome pellets were lysed in RIPA buffer with 
a protease inhibitor mixed with the sample buffer 
(Cell biolabs, CA, USA) and boiled for 5 min. 
Subsequently, the lysates were separated on a 10% 





SDS-PAGE gel (Pierce, Rockford, IL, USA) using a 
Mini-Protean TGX electrophoresis apparatus (Bio-rad, 
CA, USA). To facilitate immunoblotting, gels were 
equilibrated with a transfer buffer [250 mM Tris, 20% 
methanol (v/v), 200 mM glycine, pH 8.0] 10 min prior 
to transfer onto nitrocellulose membranes. The said 
transfer was performed via a cassette of tank transfer 
with a Mini-protean unit for 1 h at 100 V in accordance 
with the manufacturer instructions. Post transfer, the 
membranes were probed into using antibodies 
specific to albumin (R&D systems, USA). Immunod-
etection was then performed using HRP-labelled 
secondary antibodies and visualized using a LAS 4000 
detection system in accordance with the manufacturer 
protocol (Amersham, UK). 
RNA Extraction and RT-qPCR 
To analyze gene expressions, total RNA was 
extracted from EVs isolated from 200 µL of plasma 
spiked with LNEVs using the miRNeasy kit (Qiagen). 
RNA integrity and quantity were analyzed using an 
RNA pico-sensitivity kit on a bioanalyzer (Perkin-
Elmer). cDNA was prepared using a SuperScript 
VILO cDNA synthesis kit (Thermo Fisher Scientific). 
Real-time PCR was performed using the gene- 
expression master mix kit (Thermo Fisher Scientific) 
and Taqman probe with a QuantStudio 6 real-time 
PCR instrument (Thermo Fisher Scientific) using the 
following protocol: 50 °C for 2 min, 95 °C for 10 min 
followed by 40 cycles of 60 °C for 15 s, using the 
forward, probe, and reverse primers listed in Table 
S5. All samples were analyzed in triplicate. Data 
presented as mean ± SE. 
Statistical analysis 
Optical density (OD) measurements of ELISA 
assays were performed on 73 samples (i.e., 43 and 30 
samples each from prostate-cancer patients and 
healthy donors, respectively). The measured OD 
values were normalized along each biomarker for all 
samples and sorted in descending order with respect 
to the HSP90-OD level. The normalized OD values 
were visualized on a heat map (Figure 5A), and eight 
markers were validated in patients diagnosed with 
prostate cancer and healthy donors by means of a box 
plot. A student’s t-test was performed, and p-values 
below 0.05 were considered statistically to be 
signiﬁcant—here, p < 0.05, p < 0.01, p < 0.001, and p < 
0.0001 have been represented as *, **, ***, and ****, 
respectively (Figure 5B). Receiver operation charac-
teristic (ROC) curves and metrics for classifying 
prostate-cancer patients and normal donors were 
obtained for each biomarker (Figures 5C–5D and 
Figure S11). The ROC metrics, (i.e., AUC, SE, 
accuracy, sensitivity, specificity, and negative 
likelihood ratio (NLR) cutoff) were calculated using 
standard approaches. OD measurements correspond-
ing to HSP90 ELISA were depicted in the waterfall 
plot (Figure 5E). The cutoff value was given by NLR. 
All computations and visualizations were performed 
using MATLAB (MathWorks, USA) and OriginPro 
(OriginLab, USA) packages.  
SVM classification 
Binary support vector machine (SVM) classifica-
tion models were created using a set of ELISA data 
(Figure S12). The SVM models are defined with the 
third-order polynomial kernel function and are 
validated by five-fold cross-validation. All the 
computation was performed using MATLAB 
classification learner application (MathWorks).  
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